[Classification of idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific antibodies].

OBJECTIVE To investigate the classification of idiopathic inflammatory myopathies (IIM) based on clinical manifestations and myositis- specific antibodies using cluster analysis. METHODS We retrospectively analyzed the data of patients with IIM admitted in Nanfang Hospital in 2015-2019. The clinical data of the patients including serum creatine kinase (CK), interstitial lung disease (ILD), cancer, and myositis-specific antibodies were collected for two-step cluster analysis to identify the distinct clusters of patients, whose clinical characteristics were subsequently analysed. RESULTS A total of 71 patients with IIM were included in this study, including 30 (42.3%) with polymyositis (PM), 20 (28.2%) with classic dermatomyositis (DM), 16 (22.5%) with amyopathic dermatomyositis (CADM), and 5 (7.0%) with immune-mediated necrotizing myopathy (IMNM). Two-step cluster analysis identified 3 distinctive subgroups: Cluster 1 of 15 (51.7%) patients characterized by rash, positive anti-MDA5 antibody and hypoproteinemia (P < 0.05) with normal or slightly elevated CK level, mainly corresponding to CADM; Cluster 2 of 4 (57.1%) patients with significantly elevated CK and positive anti-SRP antibody (P < 0.001) corresponding to IMNM; and Cluster 3 of 17 (48.6%) patients consisting primarily of patients with PM, characterized by positivity for anti- aminoacyl transfer RNA synthetases antibodies (P=0.022) corresponding to antisynthetase syndrome (ASS). CONCLUSIONS Patients with IIM can be divided into 3 subgroups based on their clinical and serological characteristics (especially myositis-specific antibodies), and among them ASS may represent an independent IIM subgroup with unique clinical characteristics.

[1]  S. Kamphuis,et al.  Endothelial and inflammatory biomarker profile at diagnosis reflects clinical heterogeneity of juvenile dermatomyositis and is prognostic for response to treatment in two independent cohorts. , 2020, Arthritis & rheumatology.

[2]  Yong-Beom Park,et al.  Reclassification of Korean patients with polymyositis and dermatomyositis based on the Bohan and Peter criteria by the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies , 2019, The Korean journal of internal medicine.

[3]  M. Bottai,et al.  Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. , 2019, Seminars in arthritis and rheumatism.

[4]  C. Bodemer,et al.  Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. , 2019, Rheumatology.

[5]  T. Kanda,et al.  First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort , 2019, Annals of the rheumatic diseases.

[6]  I. Nishino,et al.  Classification of idiopathic inflammatory myopathies: pathology perspectives. , 2019, Current opinion in neurology.

[7]  M. Guiguet,et al.  Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies , 2018, JAMA neurology.

[8]  B. Hervier,et al.  Antisynthetase syndrome pathogenesis: knowledge and uncertainties , 2018, Current opinion in rheumatology.

[9]  C. Saris,et al.  Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[10]  H. Chinoy,et al.  Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies , 2018, Current opinion in rheumatology.

[11]  A. Mammen,et al.  Classification and management of adult inflammatory myopathies , 2018, The Lancet Neurology.

[12]  Jian-Qiang Lu,et al.  Revisiting Pathological Classification Criteria for Adult Idiopathic Inflammatory Myopathies: In-Depth Analysis of Muscle Biopsies and Correlation Between Pathological Diagnosis and Clinical Manifestations , 2018, Journal of neuropathology and experimental neurology.

[13]  P. Lachenbruch,et al.  2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups , 2017, Arthritis & rheumatology.

[14]  I. Nishino,et al.  Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology. , 2017, Autoimmunity reviews.

[15]  J. Raynauld,et al.  Editorial: A New Classification of Adult Autoimmune Myositis , 2017, Arthritis & rheumatology.

[16]  Z. Betteridge,et al.  Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis , 2016, Journal of internal medicine.

[17]  Xusheng Huang,et al.  Clinicopathologic features of sporadic inclusion body myositis in China. , 2015, Neurologia i neurochirurgia polska.

[18]  I. Lundberg,et al.  Pathogenesis, classification and treatment of inflammatory myopathies , 2011, Nature Reviews Rheumatology.

[19]  I. Targoff,et al.  Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients , 2005, Medicine.

[20]  T. Mimori,et al.  The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. , 1983, Arthritis and rheumatism.

[21]  K. Brown,et al.  Myositis-related interstitial lung disease and antisynthetase syndrome. , 2011, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.